Baxter International at a Crossroads: Can the Healthcare Giant's 2026 Vision Justify Its Current Valuation?
Baxter International's stock presents a complex picture for investors, with recent short-term gains overshadowed by a significant annual loss. As the company navigates margin pressures and pins hopes on a strategic reset by 2026, analysts debate whether its current price represents a genuine discount or a fair reflection of underlying challenges.